Your browser version may not work well with NCBI's Web applications. More information here...
1: Peptides. 2007 Sep;28(9):1631-9. Epub 2007 May 22.
Related Articles, Links
Click here to read Click here to read
Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology.

Laburthe M, Couvineau A, Tan V.

INSERM, U773, Centre de Recherche Biomédicale Bichat Beaujon, CRB3, Université Paris 7 Denis Diderot, BP416, F-75018 Paris, France. laburthe@bichat.inserm.fr

VIP and PACAP impact strongly on human pathophysiology. Their receptors are very promising targets for developing new drugs in the treatment of inflammatory and neurodegenerative diseases. This article reviews the present knowledge regarding VIP and PACAP receptors, i.e. VPAC1, VPAC2 and PAC1. This includes: (I) a critical review of instrumental peptide agonists and antagonists; (II) a survey of recent data regarding the structure of VPAC1 receptor and the docking of VIP in the receptor binding domain. Structural models for the VPAC2 and PAC1 receptor N-terminal ectodomains are also described; (III) A critical description of the two models of VPAC1 receptor activation in the general context of class II/family B G protein-coupled receptors.

Publication Types:
PMID: 17574305 [PubMed - indexed for MEDLINE]